R3HDM1

Across TCGA pan-cancer cohorts, R3HDM1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated R3HDM1 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher R3HDM1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated R3HDM1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LIHC, STAD, and PRAD are the cancer types where R3HDM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.110	0.557	<.001	18	view →
STAD	DFS	Median	II,III,IV	1.000	0.371	.031	11	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	All	0.211	0.876	.028	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

R3HDM1–LIHC (DFS)

Open the LIHC breakdown →